Evidence mapPaperPMID 41727633Full record

ArticleFrontiers in oncology2026

Genetic association of miR-146a, miR-196a2, and miR-499 polymorphisms with hepatocellular carcinoma risk in an Eastern Chinese population.

Lunjun Zhang, Qing Pang, Hongtao Wang, Tao Xu, Xiaolin Ding

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lunjun ZhangDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Qing PangThe Second Clinical Medical College of Anhui Medical University, Hefei, China.
Hongtao WangDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Tao XuDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Xiaolin DingDepartment of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the third leading cause of cancer-related mortality worldwide. MicroRNAs (miRNAs) are known to regulate oncogenic and tumor suppressor pathways, and single nucleotide polymorphisms (SNPs) in miRNAs may influence cancer susceptibility. Methods: We investigated the association between three miRNA SNPs-miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444-and the risk of HCC in an eastern Chinese population. A total of 353 HCC patients and 351 healthy controls were enrolled. Genotyping was performed using PCR-ligase detection reaction (PCR-LDR), and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: Compared with the CC genotype, individuals carrying the CT and TT genotypes of miR-196a2 rs11614913 exhibited significantly increased risks of HCC (OR = 1.61, 95% CI: 1.10-2.37; OR: 1.66, 95% CI: 1.07-2.55). The dominant model of miR-196a2 rs11614913 also showed a significant association with HCC risk ( Conclusion: Our findings suggest that miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms are significantly associated with HCC susceptibility in the eastern Chinese population and may serve as potential genetic biomarkers for early risk assessment.

Indexed as

genetic susceptibilityhepatocellular carcinomamir-146amiR-196a2miR-499miRNA polymorphism

Identifiers

PMID41727633
PMCPMC12920222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.